期刊文献+

HIV-1B/C重组毒株gp160假病毒的构建及其活性检测 被引量:1

Construction of a HIV-1 B/C recombinant subtyped pseudovirus and evaluation of its activities
原文传递
导出
摘要 目的以CD4+T细胞DNA为模板,进行gp160扩增,构建艾滋病病毒Ⅰ型(HIV-1)前病毒假病毒,通过中和试验验证其具有感染活性。方法选择高效抗反转录病毒治疗(HAART)成功的病人3例,分离外周血单核细胞(PBMC),纯化CD4+T细胞,提取DNA,以其为模板扩增gp160全长基因,并克隆到pcDNA3.1(+)表达载体上,酶切验证得到阳性克隆。将此阳性克隆和pNL4-3质粒共转染,获得HIV-1假病毒。用免疫兔血清验证假病毒的感染活性。结果成功地获得了1株假病毒。用免疫后的兔血清测定半数抑制浓度(IC50)的滴度约在1∶901∶270之间。病毒的加入量与细胞感染率之间存在良好的线性关系,说明该假病毒感染系统可以通过细胞感染率较好地反映出感染性病毒的含量。结论获得了具有感染活性的HIV-1B/C重组型假病毒。 Objective To extract viral DNA from the CD+4 T cells of the HIV-1 infected patients and to construct HIV-1 pseudotyped virus,which will serve as a useful tool for neutralization assay.Methods The blood samples were collected from HIV-1 infected patients and the peripheral blood mononuclear cells were separated.The provirus DNA was extracted and gp160 was amplified by PCR.The Env containing PCR amplicons was ligated into the pcDNA3.1(+) expression vector after appropriate restriction enzyme digestion.And then a pseudovirus-based neutralization assay was established.Results HIV pesudovirus containing luciferase gene was capable of infecting Tzm-bl cells.Conclusion The B/C recombinant subtyped pseudovirus has been successfully constructed and a platform to use a single-round replicative pseudovirus has been established.
出处 《中国艾滋病性病》 CAS 2010年第5期437-441,共5页 Chinese Journal of Aids & STD
基金 国家科技重大专项(2008ZX10001-006) 北京市科委重大项目(D09060030405912)资助~~
关键词 艾滋病病毒Ⅰ型 假病毒 中和抗体 HIV-1 Pseudovirus gp160 Neutralizating antibody
  • 相关文献

参考文献9

  • 1焦艳梅,吴昊.HIV-1潜伏库研究进展[J].首都医科大学学报,2009,30(5):639-642. 被引量:8
  • 2Yuxing Li, Stephen A Mingueles,et al. Broad HIV-1 neutralization mediated by CD4-binding site antibodies[J]. Nat Med, 2007, 13(9) : 1032-- 1035.
  • 3Eckstein DA, Sherman MP,Penn ML,et al. HIV-1 Vpr enhance viral burden by facilitating infection of tissue macrophages but not nondividing CD+ T cells[J]. J Exp Med , 2001,194 (10) : 1407 -- 1419.
  • 4Li M, Gao F, Mascola JR, et al. Human immunodeficiency virus type 1 ENV clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies [J], J Virol, 2005,79(16) : 10108--10125.
  • 5Robert-Guroff M, Brown M, Gallo RC. HTLV-III-neutralizing antibodies in patients with AIDS and AIDS-related complex[J]. Nature, 1985,316(6023) :72--74.
  • 6Mascola JR, Louder MK, Winter C, et al. Human immunodeficiency virus type 1 neutralization measured by flow cytometric quantitation of single-round infection of primary human T cells[J]. J Virol,2002,76(10) :4810--4812.
  • 7Gorny MK, Williams C,Volsky B, et al. Human monoclonal antibodies specific for conformation-sencitive epitopes of V3 neutralize human immunodeficiency virus type 1 primary isolates from various clades[J]. J Virol, 2002,76(18) :9035-9045.
  • 8Ferrantelli F, Rasmussen RA, Hofmann-Lehmann R, et al. Do not underestimate the power of antibodies-lessons from adoptive transfer of antibodies against HIV[J]. Vaccine,2002,20(Suppl 4) : A61 --A65.
  • 9Jordan A, Bisgrove D, Verdin E. HIV reproducibly establishes a latent infection after acute infection of T cell in vivo[J]. EMBO J, 2003,22(8) :1868--1877.

二级参考文献26

  • 1Ho D D,Neumann A U,Perelson A S,et al.Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection[J].Nature,1995,373:123-126.
  • 2Perelson A S,Essunger P,Can Y,et al.Decay characteristics of HIV-1-infected compartments during combination therapy[J].Nature,1997,387:188-191.
  • 3Natarajan V,Bosche M,Metcalf J A,et al.HIV-1 replication in patients with undetectable plasma virus receiving HAART.Highly active anfiretruviral therapy[J].Lancet,1999,353:119-120.
  • 4Pope M,Haase A T.Transmission,acute HIV-1 infection and the quest for strategies to prevent infection[J].Nat Med,2003,9:847-852.
  • 5Agosto L M,Yu J J,Dai J,et al.HIV-1 integrates into resting CD4+ T cells even at low inoculums as demonstrated with an improved assay for HIV-1 integration[J].Virology,2007,368:60-72.
  • 6Blazkova J,Trejbalova K,Gondois-Rey F,et al.CpG methylation controls reactivation of HIV from latency[J].PLoS Pathog,2009,5:e1000554.
  • 7Jeeninga R E,Westerhout E M,van Gerven M L,et al.HIV-1 latency in actively dividing human T cell lines[J].Retrovirology,2008,5:37.
  • 8Ramratnam B,Mittler J E,Zhang L,et al.The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy[J].Nat Med,2000,6:82-85.
  • 9Lefebvre J C,Durant J,Koechlin A,et al.HIV-1 and persistent clinical latency,TAR element analysis and improved method for in vitro viral reactivation[J].J Clin Virol,2007,38:348-352.
  • 10Fraser C,Fergusen N M,Ghani A C,et al.Reduction of the HIV-1-infected T-cell reservoir by immune activation treatment is dose-dependent and restricted by the potency of antiretroviral drugs[J].AIDS,2000,14:659-669.

共引文献7

同被引文献3

引证文献1

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部